Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272651 | 0.95 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL5273310 | 0.93 | GRIN1 (0.47) | — | |
| SCHEMBL5275202 | 0.93 | TRPV1 (0.46) | MAPK1TRPV1 | |
| SCHEMBL5324801 | 0.92 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL5271793 | 0.91 | TRPV1 (0.45) | TRPV1 | |
| SCHEMBL5274589 | 0.91 | — | — | |
| SCHEMBL5275144 | 0.91 | TRPV1 (0.44) | TRPV1 | |
| SCHEMBL4680698 | 0.88 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL5274693 | 0.85 | GRIN1 (0.48) | MAPK1 | |
| SCHEMBL5800996 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | MAPK1 676/4885TRPV1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.